搜索
Jupiter Neurosciences Inc
JUNS添加自选
0.338USD
-0.011-3.29%
收盘 05/15, 16:00（美东）报价延迟15分钟
11.64M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.29%
5天
+1.56%
1月
-15.25%
6月
-74.78%
今年开始到现在
-66.86%
1年
-42.23%
TradingKey Jupiter Neurosciences Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Jupiter Neurosciences Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名205/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价25.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Jupiter Neurosciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Jupiter Neurosciences Inc亮点
亮点风险
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
业绩增长期
公司处于发展阶段，最新年度总收入21.80K美元
利润高增长
公司净利润处于行业前列，最新年度总收入21.80K美元
估值高估
公司最新PE估值-1.29，处于3年历史高位
机构加仓
最新机构持股2.06M股，环比增加42.85%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值0.00
分析师目标
根据
1
位分析师
买入
评级
25.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Jupiter Neurosciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Jupiter Neurosciences Inc简介
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
公司代码JUNS
公司Jupiter Neurosciences Inc
CEORosen (Christer)
网址https://jupiterneurosciences.com/
相关品种
